Compare Paycom Software Inc (PAYC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Paycom Software Inc trades at $231.94 (market cap $10.36B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Paycom Software Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and Paycom Software Inc pays a 0.65% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PAYC | XBI | |
|---|---|---|
Market Cap | $10.36B | $10.11B |
Volume | 666,294 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $240.52 | $169.55 |
52-Week Low | $113.59 | $104.99 |
Typical Hold Time | 84 Days | 38 Days |
Enterprise Value | $11.15B | — |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $232.22, up 3.86% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.78 versus $2.38 expected, driven by 10% revenue growth and margin expansion. The company raised full-year 2026 guidance, targeting 7-8% revenue growth and improved EBITDA margins. Cash flow remains robust, with 2025 operating cash flow at $678.9 million.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and market volatility. Analyst consensus is mixed with a $207.75 price target below the current price, suggesting cautious optimism. Institutional buying activity supports bullish sentiment, though valuation multiples like a P/E of 24.33 warrant monitoring for sustainability.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
